Skip to main content
. 2016 Nov 28;20(4):139–145.

Figure 4.

Figure 4

Sustained virologic response (SVR) in patients with very rapid virologic response (vRVR) on 4-drug regimen that did not include peginterferon alfa. Patients in the high-dose nonstructural protein 5A antagonist group (arm 2) who achieved vRVR were randomized to 12 weeks (12-SVR) or 24 weeks (24-SVR) of therapy. Overall, 87% (26/30) of patients without vRVR had viral suppression with the addition of peginterferon alfa. Adapted with permission from Sulkowski et al.11